15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $109M | $5M | 67.3% | 10.7% | $19M | $26M | $23M |
| 2024 | $92M | -$20M | 64.5% | -14.9% | $5M | $34M | $13M |
| 2023 | — | -$18M | — | — | -$7M | $38M | $14M |
| 2022 | $1M | -$11M | 3801.6% | -1199.1% | $11M | — | $18M |
| 2021 | $5M | $378079 | 789.0% | 8.0% | $625717 | — | $85M |
| 2020 | — | -$2M | — | — | -$6M | — | $11M |
| 2019 | — | -$3M | — | — | -$2M | — | $19M |
| 2018 | — | $226344 | — | — | $758193 | — | $9M |
| 2017 | — | -$2M | — | — | -$2M | — | $5M |
| 2016 | — | -$2M | — | — | -$644399 | — | $7M |
| 2015 | — | -$595140 | — | — | $513064 | — | $8M |
| 2014 | — | -$1M | — | — | -$63334 | — | $3M |
| 2013 | — | -$267290 | — | — | $1M | — | $1M |
| 2012 | — | -$454553 | — | — | -$626263 | — | $284263 |
| 2011 | — | -$2M | — | — | -$534609 | $0 | $959166 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $20M | -$495000 | 75.2% | 2.0% | -$488000 | $24M | $20M |
| Dec '25 | $32M | $5M | 74.8% | 26.6% | $7M | $26M | $23M |
| Sep '25 | $26M | $779000 | 67.2% | 7.9% | $3M | $29M | $20M |
| Jun '25 | $29M | $2M | 63.8% | 10.9% | $5M | $29M | $17M |
| Mar '25 | $22M | -$2M | 60.9% | -9.6% | $4M | $34M | $17M |
| Dec '24 | $32M | -$78000 | 68.1% | 11.2% | $181000 | $34M | $13M |
| Sep '24 | $21M | -$9M | 63.1% | -40.2% | $2M | $37M | $16M |
| Jun '24 | $19M | -$4M | 62.2% | -19.9% | $737000 | $37M | — |
| Mar '24 | $20M | -$7M | 62.0% | -25.5% | $2M | $38M | — |
| Dec '23 | $28M | -$4M | 62.9% | -38.4% | -$6M | $38M | $14M |
| Sep '23 | $16M | -$3M | 60.0% | -21.8% | $1M | $5800 | — |
| Jun '23 | $14M | -$4M | 56.6% | -35.1% | -$2M | — | $10M |
| Mar '23 | $13M | -$6M | 57.2% | -54.3% | -$114580 | — | $16M |
| Dec '22 | $20M | -$325836 | 63.4% | -4.4% | $3M | — | $18M |
| Sep '22 | $15M | -$3M | 62.4% | -24.9% | $3M | — | $41M |
| Jun '22 | $14M | -$4M | 64.3% | -28.0% | $281273 | — | $87M |
| Mar '22 | $14M | -$4M | 59.0% | -27.4% | $4M | — | $89M |
| Dec '21 | $20M | $623462 | 61.0% | 3.1% | -$1M | — | $85M |
| Sep '21 | $16M | $39894 | 56.3% | 0.2% | $186017 | — | $85M |
| Jun '21 | $14M | $352100 | 59.0% | 2.5% | $166121 | — | $84M |
How the market has priced OPRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, OptimizeRx Corp's revenue has grown 121.9% per year. These are computed facts, not advice.
As of FY2025, OptimizeRx Corp reported $26M of total debt against $23M of cash; operating income covered interest expense 2.2×.
In FY2025, gross margin was 67.3%, operating margin 10.7%, and net margin 4.7%.
As of Jun '26, OptimizeRx Corp traded at a price-to-earnings ratio of about 18.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.